logo
  

AstraZeneca, Daiichi Sankyo: ENHERTU Demonstrated Durable Responses In Phase II Trial

AstraZeneca plc (AZN.L,AZN) and Daiichi Sankyo Co. Limited (DSKYF.PK) said Thursday that updated results from the positive DESTINY-Breast01 Phase II trial showed ENHERTU (fam-trastuzumab deruxtecan-nxki) continued to demonstrate impressive efficacy and durable responses in patients with HER2-positive metastatic breast cancer following two or more prior HER2-based regimens.

With a median duration of follow-up of 20.5 months, patients treated with ENHERTU achieved an objective response rate or ORR of 61.4 percent and a median duration of response or DoR of 20.8 months. The median progression-free survival or PFS was 19.4 months.

The updated data were presented in a Spotlight Poster Discussion at the 2020 San Antonio Breast Cancer Symposium (SABCS).

In the previous analysis at 11.1 months of follow-up, an ORR of 60.9 percent was seen with a median DoR of 14.8 months and median PFS of 16.4 months.

AstraZeneca and Daiichi Sankyo said that additional trials are ongoing to confirm the results seen in DESTINY-Breast01.

ENHERTU was approved in the U.S. and Japan for the treatment of HER2-positive, unresectable or metastatic breast cancer following two or more prior anti-HER2 based regimens in the metastatic setting based on the earlier results from the DESTINY-Breast01 trial.

In the U.S., ENHERTU was approved under FDA Accelerated Approval and confirmatory trials are underway.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Motors will start replacing defective battery modules in Chevrolet Bolt EVs and EUVs with new modules. The replacement battery modules will be shipped to dealers as soon as mid-October, the automaker said in a statement. CVS Health is set to recruit qualified candidates to fill 25,000 clinical and retail jobs during a one-day national career event on Friday, September 24. This will enable CVS to meet the high demand for pharmacists, pharmacy technicians, nurses, and retail store associates to support flu season, COVID-19 vaccinations and testing. Twitter, Inc. (TWTR) announced Monday that it has entered into a binding agreement to settle the consolidated class action lawsuit commenced in 2016 in the United States District Court for the Northern District of California. Under the terms of the proposed settlement, Twitter will pay $809.5 million...
Follow RTT